Palvella Therapeutics, Inc. Accrued Liabilities, Current
Palvella Therapeutics, Inc. (PVLA) had Accrued Liabilities, Current of $19.68 million as of 2021-09-30, per its 10-Q filed 2021-11-02.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2021-11-02
- 2021-09-30: Accrued Liabilities, Current $19.68M.
- 2021-06-30: Accrued Liabilities, Current $16.08M.
- 2021-03-31: Accrued Liabilities, Current $9.56M.
- 2020-12-31: Accrued Liabilities, Current $7.73M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2021-09-30 | $19.68M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $16.08M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $9.56M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $7.73M 10-Q · filed 2021-11-02 | |
| 2020-09-30 | $7.49M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $5.94M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $6.94M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $9.94M 10-Q · filed 2020-11-04 | |
| 2019-09-30 | $7.17M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $8.49M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $9.22M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $9.11M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $5.98M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $4.56M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $6.58M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $6.17M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $5.10M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $6.35M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $2.96M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $3.72M 10-K · filed 2018-03-15 | $3.72M 10-K · filed 2017-03-30 |
| 2016-09-30 | $2.90M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $2.33M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $2.32M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $1.74M 10-K · filed 2017-03-30 | |
| 2015-09-30 | $1.03M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $635.56K 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $413.39K 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $986.62K 10-K · filed 2016-03-23 | $743.87K 10-K · filed 2015-03-30 |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $0.00 10-Q · filed 2014-11-13 | |
| 2014-03-31 | $2.50K 10-Q · filed 2014-06-02 | |
| 2013-12-31 | $559.63K 10-K · filed 2015-03-30 | $1.25K 10-Q · filed 2014-05-14 |
| 2013-06-30 | $0.00 10-K · filed 2014-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |